Rich
At the ASCO Breast Cancer Symposium in 2008, Dr. Weisenthal had shown that Tykerb enhanced the antivascular activity of Avastin. High dose, intermittent 'bolus' schedules of Tykerb to coincide with Avastin administration may be clinically advantageous, even in Her2-negative tumors. Avastin + Tykerb may be the first clinically-exploitable antivascular activity drug combination. It will take combination antivascular (anti-angiogenesis) therapy to make a big difference in cancer medicine.
http://www.asco.org/ASCOv2/Meetings/...stractID=40418